Skip to main content
Premium Trial:

Request an Annual Quote

It's No Pfizer, But Still...

The Los Angeles Times has an article announcing Amgen's move to eliminate 2,200 to 2,600 jobs worldwide — 12 to 14 percent of the company's workforce — in response to declining sales of the anemia drug Aranesp. After the FDA put a black box warning on the drug, sales fell 19% to $578 million in the second quarter of this year, and the stock price is at the lowest it’s been in four years. While the cuts aren't as mind-blowing as those Pfizer made early this year, they're still enough to signify that the biotech industry is not immune to the changing pharma regulatory environment.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.